Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up
MoMoGains MoMoGains
NEXT ALERT COUNTDOWN
Stock Information

Deciphera Pharmaceuticals Inc. Company Name:

DCPH Stock Symbol:

NASDAQ Market:

MENU
DCPH DCPH Quote DCPH Short DCPH News DCPH Articles DCPH Message Board
Get DCPH Alerts

News, Short Squeeze, Breakout and More Instantly...

RECENT DCPH NEWS
  • DCPH - Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors

    - Former CEO of Array BioPharma Brings Expertise in Oncology Drug Development and Commercialization - Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has appointed Ro...

  • DCPH - Deciphera: Analysis Of The Market Potential Of Ripretinib

    Ripretinib is Deciphera's ( DCPH ) lead drug candidate and it is being tested in GIST, or gastrointestinal stromal tumors. Recently, the drug fared positively in a phase 3 trial called INVICTUS evaluating ripretinib in patients with fourth-line and fourth-line plus GIST. Given those result...

  • DCPH - Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman

    Accomplished Former COO of Deloitte Brings Extensive Strategic, Operational and Business Expertise Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has elected Frank ...

DCPH News and Press, Deciphera Pharmaceuticals Inc.


home / stock / dcph / dcph news

  • Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors

    - Former CEO of Array BioPharma Brings Expertise in Oncology Drug Development and Commercialization - Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has appointed Ro...

    • December 04, 2019 04:05:00 pm
    • |
    • Business Wire
    • |
      • DCPH Stock
      • DCPH Quote
      • DCPH Short
      • DCPH News
      • DCPH Articles
      • DCPH Message Board
  • Deciphera: Analysis Of The Market Potential Of Ripretinib

    Ripretinib is Deciphera's ( DCPH ) lead drug candidate and it is being tested in GIST, or gastrointestinal stromal tumors. Recently, the drug fared positively in a phase 3 trial called INVICTUS evaluating ripretinib in patients with fourth-line and fourth-line plus GIST. Given those result...

    • November 26, 2019 03:35:23 pm
    • |
    • SeekingAlpha
    • |
      • DCPH Stock
      • DCPH Quote
      • DCPH Short
      • DCPH News
      • DCPH Articles
      • DCPH Message Board
  • Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman

    Accomplished Former COO of Deloitte Brings Extensive Strategic, Operational and Business Expertise Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has elected Frank ...

    • November 26, 2019 07:00:00 am
    • |
    • Business Wire
    • |
      • DCPH Stock
      • DCPH Quote
      • DCPH Short
      • DCPH News
      • DCPH Articles
      • DCPH Message Board
  • Healthcare On The March

    Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...

    • November 21, 2019 12:07:11 pm
    • |
    • SeekingAlpha
    • |
      • DCPH Stock
      • DCPH Quote
      • DCPH Short
      • DCPH News
      • DCPH Articles
      • DCPH Message Board
  • Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting

    - Preliminary Anti-tumor Activity Observed in Initial Diffuse-type TGCT Patients Treated with DCC-3014 in Ongoing Phase 1 Study - - DCC-3014 was Generally Well Tolerated with No Reported Grade 3 or Higher TEAEs in Initial Diffuse-Type TGCT Patients - - Encore Presentation of Resul...

    • November 13, 2019 04:30:00 pm
    • |
    • Business Wire
    • |
      • DCPH Stock
      • DCPH Quote
      • DCPH Short
      • DCPH News
      • DCPH Articles
      • DCPH Message Board
  • Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that members of the management team will present at the following investor conferences: Jefferies 2019 London Healthca...

    • November 13, 2019 07:00:00 am
    • |
    • Business Wire
    • |
      • DCPH Stock
      • DCPH Quote
      • DCPH Short
      • DCPH News
      • DCPH Articles
      • DCPH Message Board
  • Blueprint Medicines: GIST Setback Unlikely To Deter Future

    Blueprint suffers GIST setbacks NDA changes Blueprint Medicines ( BPMC ) recently announced the FDA will split Avapritinib New Drug Application into separate submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST, setting the company back a quarter. In order to prioritize ...

    • November 12, 2019 12:44:44 pm
    • |
    • SeekingAlpha
    • |
      • DCPH Stock
      • DCPH Quote
      • DCPH Short
      • DCPH News
      • DCPH Articles
      • DCPH Message Board
  • 4 RNA Therapy Stocks For A Biotech Portfolio

    Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...

    • November 07, 2019 02:20:21 pm
    • |
    • SeekingAlpha
    • |
      • DCPH Stock
      • DCPH Quote
      • DCPH Short
      • DCPH News
      • DCPH Articles
      • DCPH Message Board
  • Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q3 2019 Results - Earnings Call Transcript

    Deciphera Pharmaceuticals, Inc. (DCPH) Q3 2019 Earnings Conference Call November 04, 2019, 16:30 ET Company Participants Jennifer Robinson - VP, Investor Relations Steven Hoerter - President, CEO & Director Matthew Sherman - Chief Medical Officer Tucker Kelly - CFO & Tr...

    • November 04, 2019 10:25:13 pm
    • |
    • SeekingAlpha
    • |
      • DCPH Stock
      • DCPH Quote
      • DCPH Short
      • DCPH News
      • DCPH Articles
      • DCPH Message Board
  • Deciphera Pharmaceuticals, Inc. (DCPH) Q3 2019 Earnings Call Transcript

    Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc.   (NASDAQ: DCPH) Q3 2019 Earnings Call Nov 4, 2019 , 4:30 p.m. ET Operator Continue reading

    • November 04, 2019 09:00:22 pm
    • |
    • Motley Fool
    • |
      • DCPH Stock
      • DCPH Quote
      • DCPH Short
      • DCPH News
      • DCPH Articles
      • DCPH Message Board
Next 10
  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Member Benefits
  • Member Coins
  • Sign Up
  • Login
  • Contact

Sign up or login to continue

Sign up or login to continue.




Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Member Benefits

Member Coins


Log In

Sign Up

Stay Connected
Follow @marketWN

Contact

Privacy

Terms of Service

Disclaimer

© 2018 Market Wire News